EP4530291A4 - PLATFORM FOR THE EXPRESSION OF PROTEIN OF INTEREST USING VIRAL NUCLEOCAPSIDE - Google Patents

PLATFORM FOR THE EXPRESSION OF PROTEIN OF INTEREST USING VIRAL NUCLEOCAPSIDE

Info

Publication number
EP4530291A4
EP4530291A4 EP23812102.4A EP23812102A EP4530291A4 EP 4530291 A4 EP4530291 A4 EP 4530291A4 EP 23812102 A EP23812102 A EP 23812102A EP 4530291 A4 EP4530291 A4 EP 4530291A4
Authority
EP
European Patent Office
Prior art keywords
interest
protein
expression
platform
nucleocapside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23812102.4A
Other languages
German (de)
French (fr)
Other versions
EP4530291A1 (en
Inventor
Myung Hyun Sohn
Do Da Kim
Seong Hyun Park
Sung Jae Kim
Seung Hoo Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Industry Foundation UIF of Yonsei University
Original Assignee
University Industry Foundation UIF of Yonsei University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Industry Foundation UIF of Yonsei University filed Critical University Industry Foundation UIF of Yonsei University
Publication of EP4530291A1 publication Critical patent/EP4530291A1/en
Publication of EP4530291A4 publication Critical patent/EP4530291A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP23812102.4A 2022-05-23 2023-05-23 PLATFORM FOR THE EXPRESSION OF PROTEIN OF INTEREST USING VIRAL NUCLEOCAPSIDE Pending EP4530291A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20220062789 2022-05-23
PCT/KR2023/006958 WO2023229328A1 (en) 2022-05-23 2023-05-23 Platform for expressing protein of interest using viral nucleocapsid

Publications (2)

Publication Number Publication Date
EP4530291A1 EP4530291A1 (en) 2025-04-02
EP4530291A4 true EP4530291A4 (en) 2025-12-31

Family

ID=88919674

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23812102.4A Pending EP4530291A4 (en) 2022-05-23 2023-05-23 PLATFORM FOR THE EXPRESSION OF PROTEIN OF INTEREST USING VIRAL NUCLEOCAPSIDE

Country Status (5)

Country Link
EP (1) EP4530291A4 (en)
JP (1) JP2024545113A (en)
KR (1) KR102617593B1 (en)
CN (1) CN118475592A (en)
WO (1) WO2023229328A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240429A1 (en) * 2018-06-14 2019-12-19 (주) 에빅스젠 Pharmaceutical composition for treating severe complex immunodeficiency comprising fusion protein of cell penetrating peptide and adenosine deaminase
KR102264535B1 (en) * 2020-06-01 2021-06-14 (주)인테라 Recombinant expression vector for production of encapsulin-based vaccine and method for manufacturing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6316190B1 (en) * 1996-05-20 2001-11-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
KR100368073B1 (en) * 1999-03-09 2003-01-24 한국생명공학연구원 Preparation of Peptides by Use of Human Glucagon Sequence as a Fusion Expression Partner
FR2899902B1 (en) * 2006-04-18 2012-01-27 Agronomique Inst Nat Rech N-PROTEIN FUSION PROTEINS OF A PARAMYXOVIRIDAE-PROTEIN FAMILY VIRUS OF INTEREST AND USES THEREOF FOR VACCINATION AND INTRA-CELL VECTORIZATION
KR100844497B1 (en) * 2007-01-22 2008-07-08 연세대학교 산학협력단 Cell penetrating fusion protein, polynucleotide encoding the same and recombinant expression vector expressing the same
US8088392B2 (en) * 2007-06-18 2012-01-03 Yunxu Cao Capsid proteins and uses therefore
KR101360375B1 (en) * 2011-08-19 2014-02-10 연세대학교 산학협력단 Recombinant E. coli producing soluble BMP-2 and method for producing soluble BMP-2 using the same
KR101658081B1 (en) * 2015-01-15 2016-09-20 고려대학교 산학협력단 Method for Preparing Recombinant Protein Using CysQ as a Fusion Expression Partner

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019240429A1 (en) * 2018-06-14 2019-12-19 (주) 에빅스젠 Pharmaceutical composition for treating severe complex immunodeficiency comprising fusion protein of cell penetrating peptide and adenosine deaminase
KR102264535B1 (en) * 2020-06-01 2021-06-14 (주)인테라 Recombinant expression vector for production of encapsulin-based vaccine and method for manufacturing the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JAVANBAKHT HASSAN ET AL: "The Interaction between HIV-1 Gag and Human Lysyl-tRNA Synthetase during Viral Assembly", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 30, 1 July 2003 (2003-07-01), US, pages 27644 - 27651, XP093339228, ISSN: 0021-9258, DOI: 10.1074/jbc.M301840200 *
LEE N.: "Zinc finger-dependent HIV-1 nucleocapsid protein-TAR RNA interactions", NUCLEIC ACIDS RESEARCH, vol. 31, no. 16, 15 August 2003 (2003-08-15), GB, pages 4847 - 4855, XP093339341, ISSN: 1362-4962, DOI: 10.1093/nar/gkg679 *
MOUHAND ASSIA ET AL: "Overview of the Nucleic-Acid Binding Properties of the HIV-1 Nucleocapsid Protein in Its Different Maturation States", VIRUSES, vol. 12, no. 10, 29 September 2020 (2020-09-29), CH, pages 1109, XP093339342, ISSN: 1999-4915, DOI: 10.3390/v12101109 *
See also references of WO2023229328A1 *
SEONG IL CHOI ET AL: "Protein Solubility and Folding Enhancement by Interaction with RNA", PLOS ONE, vol. 3, no. 7, 16 July 2008 (2008-07-16), pages e2677, XP055106439, DOI: 10.1371/journal.pone.0002677 *

Also Published As

Publication number Publication date
JP2024545113A (en) 2024-12-05
KR102617593B1 (en) 2023-12-29
CN118475592A (en) 2024-08-09
KR20230163939A (en) 2023-12-01
WO2023229328A1 (en) 2023-11-30
KR102617593B9 (en) 2025-04-04
EP4530291A1 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
EP3722430A4 (en) Novel PROMOTOR AND METHOD FOR MANUFACTURING PURINE NUCLEOTIDE USING THEREOF
EP3755803A4 (en) CONTROLLED EXPRESSION OF TRANSGENES USING DNA (CEDNA) VECTORS
EP3674313A4 (en) NOVEL POLYPEPTIDE AND METHOD OF MANUFACTURING IMP WITH USING THEREOF
EP3674312A4 (en) NOVEL POLYPEPTIDE AND METHOD OF MANUFACTURING IMP WITH USING THEREOF
EP4065114C0 (en) METHOD FOR THE PREPARATION OF RELUTRIGINE/PRAX-562
EP3725800A4 (en) CAMP RECEPTOR PROTEIN MUTANTS AND METHOD FOR MANUFACTURING L-AMINO ACID USING THE SAME
EP3914716A4 (en) PLATFORM FOR PRODUCTION OF GLYCOPROTEINS FOR IDENTIFICATION OF GLYCOSYLATION SIGNALING PATHWAYS
EP4116314C0 (en) METHOD FOR THE PREPARATION OF 16ALPHA-HYDROXYPREDNISOLONE
EP4330413A4 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR COCHLEA TRANSDUCTION
EP3987353C0 (en) METHOD FOR PRODUCING BRIDGE WAVEGUIDES
EP3920956A4 (en) METHODS OF USE OF GLYCOSYLATED THERAPEUTIC PROTEINS
EP4530291A4 (en) PLATFORM FOR THE EXPRESSION OF PROTEIN OF INTEREST USING VIRAL NUCLEOCAPSIDE
EP4063491C0 (en) COMPOSITION FOR CULTIVATION OF NATURAL KILLER CELLS AND METHOD FOR PRODUCING NATURAL KILLER CELLS USING THE SAME
EP4057826C0 (en) PROCESS FOR PRODUCING PROTEIN MASS
EP4453189A4 (en) METHOD FOR THE PROCUREMENT OF CONEPIC PHOTORECEPTOR CELLS
EP3920888A4 (en) FUSOGENIC LIPIDNANOPARTICLES FOR TARGET CELL-SPECIFIC PRODUCTION OF RAPAMYCIN-INDUCABLE THERAPEUTIC PROTEINS
EP4195620C0 (en) PLATFORM FOR DISTRIBUTION OF MEDIA CONTENT
EP3778865A4 (en) Novel cell and method for making a protein of interest using it
EP4480252A4 (en) PROCEDURE FOR PROVIDING UAV-TO-EVERYTHING PARAMETERS
EP4049973A4 (en) METHOD OF FIXING CARBON DIOXIDE
EP3986400C0 (en) METHODS AND INTERMEDIATES FOR THE PREPARATION OF DIAZASPIROLACTAM COMPOUNDS
EP3802821A4 (en) PROCEDURE FOR DIRECT SEQUENCING OF NUCLEIC ACIDS
EP4273131C0 (en) Processes and intermediates for the preparation of carbaprostacyclin analogues
EP4021469A4 (en) IMPROVED PRODUCTION OF RECOMBINANT AAV USING EMBRYONIZED BIRD EGGS
EP4371992C0 (en) METHOD FOR THE PRODUCTION OF GLUFOSINATE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240605

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20251201

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/005 20060101AFI20251125BHEP

Ipc: C12N 15/70 20060101ALI20251125BHEP